Abstract
To determine the role of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) in extranodal NK/T-cell lymphoma patients, we conducted a retrospective analysis. In our previous study, we searched for patients who had received HDC/ASCT and identified 16 eligible patients and compared the treatment outcome with historical control group (n=246). Nine patients received HDC/ASCT in the first (CR1) or second complete remission (CR2), while seven patients received HDC/ASCT as salvage. Twelve of 16 patients achieved or maintained CR after HDC/ASCT. Among the 12 patients, five patients relapsed. Estimated 2-year overall survival (OS) and relapse-free survival (RFS) rates were 71.3±12.4% and 25.8±14.3%, respectively. There was a tendency of better survival in patients who received HDC/ASCT as compared to those who did not (P=0.091). In subset analysis, patients who underwent HDC/ASCT at CR (P=0.049) and patients with stage III or IV (P=0.001) had a favorable outcome. Patients with NKIPI 3,4 or EUNKTL, who underwent HDC/ASCT had more prolonged survival without statistical significance (P=0.055 and 0.056). In conclusion, HDC/ASCT may be considered as a treatment option for patients with extranodal NK/T-cell lymphoma, especially those in CR, with advanced disease (stage III/IV or EUNKTL) and high NKIPI scores.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821–829.
Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16: 206–214.
Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW . Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182–190.
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54–63.
Kim GE, Lee SW, Chang SK, Park HC, Pyo HR, Kim JH et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001; 61: 261–269.
Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349–352.
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 1402–1408.
Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005; 92: 1226–1230.
Liang R, Chen F, Lee CK, Kwong YL, Chim CS, Yau CC et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant 1997; 19: 91–93.
Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH et al. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. Leuk Lymphoma 2005; 46: 1743–1748.
Koizumi K, Fujimoto K, Haseyama Y, Endo T, Nishio M, Yokota K et al. Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma. Eur J Haematol 2004; 72: 140–144.
Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma 2001; 42: 1297–1303.
Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673–1676.
Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716.
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH et al. Extranodal NK/T-Cell Lymphoma, nasal-type: a prognostic model from a retrospective multi-center study. J Clin Oncol 2006; 24: 612–618.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.
Ko YH, Cho EY, Kim JE, Lee SS, Huh JR, Chang HK et al. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology 2004; 44: 480–489.
Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.
Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.
Bang SM, Kim Y-K, Park YH, Sohn SK, Lee J-J, Cho EK et al. High dose therapy and autologous stem cell transplant-ation in Korean patients with aggressive T/NK-cell lymphoma. Leuk Lymphoma 2006; 46: 1599–1602.
Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561–567.
Makita M, Maeda Y, Takenaka K, Shinagawa K, Sunami K, Hiramatsu Y et al. Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol 2002; 76: 94–97.
Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 425–431.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, H., Bang, S., Lee, J. et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 37, 819–824 (2006). https://doi.org/10.1038/sj.bmt.1705349
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705349
Keywords
This article is cited by
-
NK/T Cell Lymphoma: Updates in Therapy
Current Hematologic Malignancy Reports (2018)
-
Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center
International Journal of Hematology (2018)
-
Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature
BMC Urology (2017)
-
Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma
Indian Journal of Hematology and Blood Transfusion (2017)
-
Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL
Bone Marrow Transplantation (2016)